AlphaMadera's AlphaVal page classifies BioMarin Pharmaceutical Inc. as a Platform & Compounding FCF business and values it using Two-stage FCF DCF, then compares the result to the current market price to flag BMRN as undervalued, fairly valued, or overvalued.

What is BioMarin Pharmaceutical Inc.'s fair value?

Fair value for BMRN comes from a Two-stage FCF DCF model -- the approach AlphaVal selected for this company's Platform & Compounding FCF classification. The live AlphaVal page shows bear, base, and bull scenarios alongside the key assumption behind each.

How does AlphaMadera value BMRN?

AlphaVal routes each company to one of ten valuation archetypes based on its business model. BMRN was classified as Platform & Compounding FCF and is valued using Two-stage FCF DCF, built from BMRN's most recent reported fundamentals.

BMRN - BioMarin Pharmaceutical Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $90.94 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 80% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Undervalued Strong

Trading 40.4% below fair value

Current Price $55.21

Bear Case $63.04 14.2% upside ($63.04 - $55.21) / $55.21 = 14.2% 8% stage 1 growth, 11% discount

Fair Value $92.66 67.8% upside ($92.66 - $55.21) / $55.21 = 67.8% 14% stage 1 growth, 11% discount

Bull Case $124.64 125.8% upside ($124.64 - $55.21) / $55.21 = 125.8% 18% stage 1 growth, 11% discount

Adjust Assumptions

DCF Stage 1 Growth Rate

13.7%

Discount Rate (WACC)

11.0%

Terminal Growth Rate

3.0%

Key Value Driver

FCF growth rate (14% base case)

Terminal Value % of EV 42%

Implied Market Multiple 16.4x

Market is pricing in (growth) 6.3% vs our 13.7% base

Plain-Language Summary

Using a two-stage FCF DCF with 14% growth decelerating over 15 years, discounted at 11%, the base-case intrinsic value is $92.66 per share.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (41 analysts) $90.94

Analyst Range $59.00 – $122.00

Divergence from AlphaVal 2%

Warnings

⚠ Stock-based employee pay equals 52% of profits. This dilutes existing shareholders, so cash flow alone overstates what owners really earn.

Key Risks

P/E alone misleads — earnings depressed by growth investment
Cyclical or commodity businesses may be misclassified as platforms
Terminal value dominance suggests sensitivity to long-run assumptions